Chong Kun Dang to exclusively distribute and sell Bayer's Nexavar and Stivarga
Chong Kun Dang Pharmaceutical has signed an agreement with Bayer Korea to exclusively distribute Nexavar (sorafenib tosylate (micronized)) and Stivarga (regorafenib) for treating advanced hepatocellular carcinoma (HCC) in Korea.
Under the agreement, starting in February, Chong Kun Dang Pharm will be responsible for the exclusive distribution, sales, and marketing of Nexavar and Stivatga in hospitals and clinics in Korea.
Nexavar and Stivarga are targeted therapies for HCC. In 2018, Stivarga became the first second-line treatment for HCC to be covered by health insurance in Korea, making it a reimbursed treatment option that can be continued alongside the first-line treatment Nexavar. Since their launches, both treatments have accumulated clinical evidence through clinical trials and real-world studies.
Chong Kun Dang and Bayer Korea have been co-marketing the antibiotics Ciproby (ciprofloxacin) and Avelox (moxifloxacin) since 2005, and Kerendia (finerenone) for chronic kidney disease with type 2 diabetes since 2024. In addition, Bayer Korea's cardiovascular drugs Aspirin Protect (acetylsalicylic acid) and Adalat Oros (nifedipine) are distributed exclusively by Chong Kun Dang.
“Chong Kun Dang has recently strengthened its expertise in the anticancer division by establishing a dedicated anticancer organization,” Chong Kun Dang Pharm CEO Kim Young-joo said. “With the exclusive distribution of Nexavar and Stivarga, we will have a more robust portfolio of anticancer drugs and look forward to further expanding our presence in the domestic anticancer market.”
Bayer Korea CEO Lee Jin-ah said, “Based on our long-standing trust, we are pleased to partner with Chong Kun Dang Pharmaceutical, a company with differentiated competitiveness in the field of anticancer drugs, to provide Bayer products.
Lee added that this partnership will help improve the quality of life for liver cancer patients in Korea by making treatment options like Nexavar and Stivarga more accessible.